

The Frequency of Anticardiolipin Antibodies and Genetic Mutations Associated with Hypercoagulability Among Patients with Wegener's Granulomatosis with and without History of a Thrombotic Event

JODI K. SEBASTIAN, BARBARA VOETSCH, JOHN H. STONE, ZURINA ROMAY-PENABAD, GRACE H. LO, NANCY B. ALLEN, JOHN C. DAVIS Jr, GARY S. HOFFMAN, W. JOSEPH McCUNE, E. WILLIAM St. CLAIR, ULRICH SPECKS, ROBERT SPIERA, JOSEPH LOSCALZO, SILVIA PIERANGELI, and PETER A. MERKEL, for the Wegener's Granulomatosis Etanercept Trial Research Group

ABSTRACT. Objective. Venous thrombotic events (VTE), including both deep venous thrombosis and pulmonary emboli, are now recognized as an important complication of Wegener's granulomatosis (WG), but the mechanism(s) of this occurrence is unclear. The frequency of anticardiolipin antibodies (aCL), anti- β_2 -glycoprotein antibodies (anti- β_2 -GP), and several genetic hypercoagulable factors were examined in a large cohort of patients with WG.

Methods. One hundred eighty patients with active WG had serum and DNA samples collected upon entry into a clinical trial. Of the 180 patients, 29 patients had VTE — 13 before trial entry, 16 during trial. aCL (IgG, IgM, and IgA) and anti- β_2 -GP (IgG and IgM) were evaluated in 176 patients. Factor V Leiden (FVL), the prothrombin gene mutation (G20210A, PGM), and methylenetetrahydrofolate reductase (MTHFR) gene mutation were tested in the 29 patients with thrombotic events, and 36 patients without.

Results. aCL occurred with increased frequencies in patients with WG when compared to the general population (1%–5%): 12% had aCL and 3% had anti- β_2 -GP. There was no difference in the prevalences of aCL or anti- β_2 -GP based on clotting status. The prevalence of the genetic hypercoagulable factors examined in patients with WG was comparable to the reported rates in the general population.

Conclusion. Although the incidence of clinically significant VTE is increased in patients with WG, this increased risk is not explained by increased prevalences of aCL, anti- β_2 -GP, FVL, or mutations in PGM or MTHFR. These observations suggest a need to search for new genetic or acquired prothrombotic abnormalities to account for the increased thrombotic event rate in patients with active WG. (First Release Oct 1 2007; J Rheumatol 2007;34:2446–50)

Key Indexing Terms:

ANTICARDIOLIPIN ANTIBODIES

WEGENER'S GRANULOMATOSIS

THROMBOTIC EVENTS

Wegener's granulomatosis (WG) is a small-vessel systemic vasculitis with manifestations that often include upper and lower airway disease, glomerulonephritis, and other organ

system manifestations. Recently, venous thrombosis has been associated with WG^{1,2}. A 20-fold increase in venous thrombotic events (VTE) was observed among the 180

From Boston University School of Medicine; Tufts University School of Medicine; Brigham and Women's Hospital, Boston, Massachusetts; Johns Hopkins University, Baltimore, Maryland; University of Texas Medical Branch, Galveston, Texas; Duke University, Durham, North Carolina; University of California San Francisco, San Francisco, California; Cleveland Clinic, Cleveland, Ohio; University of Michigan, Ann Arbor, Michigan; Mayo Clinic, Rochester, Minnesota; and Hospital for Special Surgery, New York, New York, USA.

Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH P60 AR047785-06.

The WGET trial was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH N01-AR92240, and the Office of Orphan Products, FDA (grant FD-R-001652), General Clinical Research Center Grants M01-RRO-00533 (Boston University), M01-RRO-0042 (The University of Michigan), M01-RR-30 (Duke University), and M01-RRO-2719 (Johns Hopkins University School of Medicine), from the National Center for Research Resources/NIH. Drs. Stone, Merkel, and St. Clair were supported by NIAMS grants K24 AR049185-01, K24 AR2224-01A1, and K24 AR02126-04. Dr. Loscalzo's laboratory is supported by

NHLBI grants R01 HL617995, R01 HL58796, P01 HL55993, and P01 HL28178. Dr. Pierangeli's laboratory is supported by NIH grants G12-RR-03034 and SO2-GMM-08248.

J.K. Sebastian, MD; B. Voetsch, MD, PhD; P.A. Merkel, MD, MPH, Boston University School of Medicine; J.H. Stone, MD, MPH, Johns Hopkins University; Z. Romay-Penabad, PhD; S. Pierangeli, PhD, University of Texas Medical Branch; G.H. Lo, MD, MPH, Tufts University School of Medicine; N.B. Allen, MD; E.W. St. Clair, MD, Duke University; J.C. Davis Jr, MD, MPH, University of California, San Francisco; G.S. Hoffman, MD, MS, Cleveland Clinic; W.J. McCune, MD, University of Michigan; U. Specks, MD, Mayo Clinic; R. Spiera, MD, Hospital for Special Surgery; J. Loscalzo, MD, PhD, Brigham and Women's Hospital.

Address reprint requests to Dr. P.A. Merkel, Section of Rheumatology and the Clinical Epidemiology Unit, Vasculitis Center, E533, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118. E-mail: pmerkel@bu.edu

Accepted for publication June 27, 2007

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2007. All rights reserved.

patients enrolled in the Wegener's Granulomatosis Etanercept Trial (WGET) when compared to the general population^{1,3}. Even more striking, perhaps, is the finding that the incidence of VTE in WG is more than 7 times higher than in systemic lupus erythematosus (SLE), an inflammatory rheumatic disease known to be associated with a hypercoagulable state. In contrast to SLE, however, in which a number of hypercoagulable risk factors have been identified, predisposing variables for clotting are unknown in WG. Although there appears to be an association between thrombosis and active vasculitis, the pathophysiology leading to thrombosis is not known.

Several genetic mutations and acquired risk factors have been associated with thrombosis in the general population and in groups of patients with other autoimmune diseases⁴⁻⁶. Evaluating the prevalence of such factors in WG is the first step in understanding the pathophysiology of VTE among patients with this disease and ultimately in devising effective therapies. Our study examined the prevalence of several hypercoagulable factors in patients with WG with and without VTE through the testing of baseline samples from the WGET. Understanding the relationships of hypercoagulable factors with VTE in WG could have important clinical implications and would provide further insight into the pathophysiology of VTE in this disease.

MATERIALS AND METHODS

Trial design. Details of the study design and primary results of the WGET have been reported^{3,7,8}. The WGET was a randomized, double-blind, placebo-controlled trial of standard therapy with the addition of etanercept or placebo for patients with active WG.

Study subjects. The WGET had 180 study subjects. During the trial, 16 subjects had VTE. In addition, 13 subjects had VTE prior to enrollment in the study. WG status at the time of VTE in subjects that had events before enrollment was available for 12 of the 13 patients and was active in 10 of the 13 patients¹. Thrombosis rates did not differ based on whether the patient received etanercept or placebo as a part of the trial¹.

Anticardiolipin antibodies (aCL) and anti- β_2 -glycoprotein antibodies (anti- β_2 -GP) were evaluated in 176 of the 180 WGET subjects. Four patients did not have baseline serum samples available for analysis. The 29 subjects with VTE were evaluated for genetic hypercoagulable factors. An additional 36 subjects without thrombosis were randomly selected for the same genetic testing.

Ascertainment of VTE. Details of the methods used to diagnose and confirm cases of VTE (deep vein thrombosis and/or pulmonary embolism) has been published¹. For all cases, including those that occurred prior to the study, the VTE in WGET were diagnosed by clinical symptoms and then confirmed by diagnostic tests including vascular ultrasound, impedance plethysmography, ventilation-perfusion scan, computed tomographic angiography, spiral computed tomography, venography, or angiography. Study physicians completed a standardized thrombosis form for each event, recording information from the patient, non-study physicians, and medical records. These forms included the date of event, clinical details, diagnostic test results, and WG disease activity status¹.

Study specimens. Serum and whole blood (DNA) specimens were collected from all subjects in WGET at their baseline visit. They were stored at -80°C and shipped on dry ice. All laboratory personnel were blinded to the VTE status of all subjects.

aCL and anti- β_2 -glycoprotein I (anti- β_2 -GPI) studies. The titers of aCL

(IgG, IgM, and IgA) and anti- β_2 -GPI (IgG and IgM) were measured at the Morehouse School of Medicine Antiphospholipid Standardization Laboratory using an ELISA test with a positivity cutoff of 10 units⁹⁻¹³. The standardized aCL ELISA was established initially with 200 samples and recently reevaluated in a joint study with The Binding Site in the UK using 1000 samples from healthy donors, with no change in the aCL cutoff values¹⁴. Anti- β_2 -GPI IgG and IgM titers were obtained using the Quanta-Lite™ kit (Inova Diagnostics, San Diego, CA, USA) following the manufacturer's instructions. Twenty standard M units (SMU) was used as a cutoff point, as established by the manufacturer in 1996 at the 7th International Symposium on Antiphospholipid Antibodies¹⁵. Samples from the baseline visit were selected for investigation in this study because all participants had active disease at the time of enrollment and the majority of thrombotic events occurred prior to baseline or within several weeks of the baseline evaluation.

Genetic studies. Testing for the identification of the factor V Leiden (FVL) mutation, the prothrombin gene mutation (G20210), and the methylenetetrahydrofolate reductase (MTHFR) gene mutation was performed in the Boston University Whitaker Cardiovascular Institute Laboratory. Genomic DNA was obtained from leukocytes by standard phenolchloroform extraction. FVL, the G20210A mutation in the prothrombin gene, and the 677 C-T substitution in the MTHFR gene were determined by polymerase chain reaction (PCR) and restriction digestion, according to published methods¹⁶⁻¹⁸. Digested PCR products were separated by electrophoresis on 2.5% ethidium-bromide stained agarose gel¹⁹.

RESULTS

aCL. The results of testing for aCL and anti- β_2 -GP antibodies are summarized in Table 1. Twenty-one of the 176 samples tested (12%) had elevated titers of aCL. However, none of the patients evaluated had high positive titers of IgG, IgM, or IgA aCL. Three of the 29 patients (10%) with WG and VTE were positive for aCL IgM (titers 11.2 MPL, 20.3 MPL, and 38.9 MPL, respectively, corresponding to medium- or low-titer results). One patient who did not experience a VTE had a positive aCL IgG, with a titer of 16.6 GPL. Seventeen patients without VTE had elevated aCL IgM. Among these patients, 60% were in the low-positive range (10.1 to 20.0 MPL) and 40% were in the moderately-positive range (between 20.1 and 80 MPL). No patient had detectable IgA aCL at their baseline visit.

anti- β_2 -GP antibodies. No participants with thrombosis had increase titers of anti- β_2 -GP; 5 of the 147 patients without thrombosis (3%) were positive for anti- β_2 -GP.

Genetic studies. The results of the genetic studies are summarized in Table 2. Among the 65 subjects with WG evaluated for genetic abnormalities, 1 patient (1.5%) had FVL mutation, 2 patients (3%) had the prothrombin gene mutation, and 2 patients (3%) were homozygous for the MTHFR mutation. One patient had both prothrombin and MTHFR gene mutations. Among the patients without VTE, 4 (12%) were homozygous for the MTHFR gene mutation. None of the patients with genetic abnormalities were positive for aCL or anti- β_2 -GP. Of note, all 3 of the patients found to have FVL and prothrombin gene abnormalities experienced clinically significant VTE. Overall, 57/65 (88%) with WG had none of the abnormalities investigated. Four (14%) of the 29 patients with a history of VTE and 4 (11%) of the 36

Table 1. Anticardiolipin and anti- β_2 -GP antibodies in study subjects with Wegener's granulomatosis with and without thrombosis.

	aCL IgG	aCL IgM	aCl IgA	Any aCl Antibody	Anti- β_2 -GP IgG	Anti- β_2 -GP IgM	Any Anti- β_2 -GP	Any aCL or Any Anti- β_2 -GP	Any Anti- β_2 -GP and Any aCL
VTE, n = 29	0	3	0	3 (10%)	0	0	0	3	0
No VTE, n = 147	1	17	0	18 (13%)	1	5	5* (3.4%)	23	3
Total, n = 176	1	20	0	21 (12%)	1	5	5* (2.8%)	26	3

aCL: anticardiolipin antibodies; anti- β_2 -GP: β_2 -glycoprotein antibodies; VTE: venous thrombotic event. *1 patient both anti- β_2 -GP IgM and IgG-positive.

Table 2. Genetic hypercoagulable factors in study subjects with Wegener's granulomatosis with and without thrombosis.

	Factor V Leiden Mutation Heterozygous	Prothrombin Gene Mutation (G20210A) Heterozygous	MTHFR Mutation Homozygous	Any of 3 Abnormalities	None of 3 Abnormalities
VTE, n = 29 (%)	1 (3)	2* (7)	2* (7)	4 (14)	25 (86)
No VTE, n = 36 (%)	0	0	4 (12)	4 (12)	32 (88)

MTHFR: methylenetetrahydrofolate reductase mutation; VTE: venous thrombotic event. *1 patient both heterozygous for the prothrombin gene mutation and homozygous for MTHFR mutation.

patients without a history of VTE had at least one of the 3 genetic mutations evaluated. Additionally, heterozygosity for the MTHFR mutation was found in 34 of 65 (52%) of the patients with WG: 14/29 (48%) with and 20/36 (56%) without VTE. However, MTHFR heterozygosity is not considered a significant risk factor for thrombotic events.

DISCUSSION

Our results refute the concepts that aCL, anti- β_2 -GP, or the common genetic risk factors evaluated in our study explain the high incidence of VTE in patients with WG. This knowledge is important because it allows investigators to pursue different explanations in understanding this phenomenon. Although aCL antibodies occurred with an increased frequency (12%) in our cohort with WG compared to the general population, they were found generally in low titers and were not increased specifically among the group of patients with WG who experienced VTE. aCL are found in 1%–5% of healthy controls, with slight increase in prevalence among elderly and chronically ill patients^{6,20}. In patients who have idiopathic VTE, aCL and anti- β_2 -GP antibodies have been reported in increased prevalence of 5% to 30%^{6,20-22}.

In this cohort of patients with WG, the rates of FVL (1%), prothrombin (3%), and MTHFR (9%) gene mutations were not different when compared to the rate in the general population. In the general population, the rates of FVL, prothrombin gene mutation, and MTHFR range up to 8%, 6.5%, and 15%, respectively, with some estimates in each case being substantially lower^{5,6,19,23,24}. Among the 29 patients with WG and with a history of VTE, only 4 (14%) were positive for at least 1 of the 3 genetic mutations evalu-

ated. In contrast, in a study of 162 patients with idiopathic VTE, 75 (40%) were found to have mutations in FVL, prothrombin gene mutation, or the MTHFR mutation⁵.

Of note, all 3 of the patients found to have FVL and prothrombin gene abnormalities had clinically significant thrombosis. One patient with a documented VTE had both prothrombin and the MTHFR gene mutations. The combination of a mutation in MTHFR with either FVL or the prothrombin gene mutation greatly increases the risk of venous thrombosis in the general population²⁴. Although these mutations may have been a factor in the development of a VTE in these 3 patients, these factors clearly cannot explain most of the increased risk of VTE in WG. Thus, while the hypercoagulable factors examined in our study, when present, add to the risk for thrombosis in patients with WG, the number of study subjects with these abnormalities was quite small, and definitive recommendations in regard to screening for these genetic mutations cannot be made.

In our study, 21 of 176 (12%) patients with WG had aCL, including 3 of 29 (10%) patients with thrombosis. The prevalence of aCL among patients with WG has been investigated, and those studies are summarized in Table 3. Similar to our study, all of the listed studies demonstrate an increased frequency of aCL in patients with WG; however, there does not appear to be a relationship between aCL and the increase in thromboses.

There are several notable strengths of our study. This project involved prospectively collected data from a large cohort of patients with well characterized WG. Further, a standardized protocol was used to ascertain and confirm thrombotic events. Laboratory procedures for the assay of hypercoagulable factors were performed by experts in the

Table 3. Frequencies of anticardiolipin antibodies (aCL) and anti- β_2 GP antibodies among patients with Wegener's granulomatosis.

Reference*	Sample Size of Patients with WG	Prevalence of aCL (either IgG or IgM) (%)	No. with Thrombosis	Prevalence of aCL in Patients with Thrombosis (%)	Prevalence of Anti- β_2 -GP (%)
Hergesell ²⁵	29	1 (3.4)	NA	NA	NA
Merkel ²⁶	52	2 (3.8)	NA	NA	NA
Hansen ²⁷	36	7 (19)	6	2 (29)	0 (0)
Lamprecht ²⁸	67	32 (48)	11	4 (36)	NA**
Meyer ²⁹	26	3 (12)	0	0 (0)	NA
Von Scheven ³⁰	5	3 (60)	5	3 (60)	1 (20)
Present study	176	21 (12)	29	3 (10)	5 (2.8)

* An additional study examined aCL among patients with WG but did not specify the frequency of positive tests³¹. ** Did not separate the presence of aCL from anti- β_2 -GP. NA: not available.

field. This is the largest study to measure aCL and anti- β_2 -GP in patients with WG and the first study to screen a population of patients with WG for the currently known genetic risk factors for hypercoagulability.

Our study also has some limitations. Levels of aCL and anti- β_2 -GP may be affected by immunosuppressive medications; however, the baseline visit in the WGET came within one month of initiation of new immunosuppressive medication doses and glucocorticoids in all patients. Although levels of aCL and anti- β_2 -GP would ideally have been measured at the time of thrombosis, such timing was not possible and it is unlikely that it would have changed the conclusion that these antibodies are not responsible for the increased rate of thrombosis in the patients with WG. Second, the types of samples available for testing did not permit us to screen for the frequencies of protein C and S deficiencies and lupus anticoagulant activity, all of which are established risk factors for hypercoagulable states. However, these potential risk factors (along with the antithrombin III gene mutation) have been investigated by others, without the identification of positive associations².

Our study provides evidence that aCL, anti- β_2 -GP antibodies, FVL, the prothrombin gene mutation, or the MTHFR gene mutation do not explain, either alone or in combination, the increased prevalence of thrombosis in patients with WG. The contribution of many acquired risks for VTE, such as proteinuria, neuropathy, bed rest, obesity, smoking, and hormone replacement, were partially evaluated in this cohort of patients previously published by Merkel, *et al*¹, as well as in a case series of patients in Weidner, *et al*². In addition to these acquired risk factors, inflammation, inflammatory cytokines, endothelial cell damage, endothelial cell antibodies, or a combination of the above with acquired risk factors could all play a role in the pathophysiology of VTE in patients with WG, and have not yet been thoroughly investigated, but should be the focus of future WG research. Additionally, the venous involvement observed in WG differs substantially from patterns of vasculitic involvement known to occur in other major forms of

vasculitis, e.g., polyarteritis nodosa, giant cell arteritis, and Takayasu's arteritis, and may be an important contributing factor to the occurrence of VTE in this population.

These observations suggest a need to search for additional prothrombotic abnormalities including genetic mutations, inflammatory mediators, or endothelial cell abnormalities, to account for the increased thrombotic event rate in patients with active WG.

APPENDIX

The WGET Research Group

WGET Chairman: John H. Stone, MD, MPH, The Johns Hopkins Vasculitis Center. WGET Co-Chairman: Gary S. Hoffman, MD, The Cleveland Clinic Foundation Center for Vasculitis Research and Care.

Coordinating Center: The Johns Hopkins University Center for Clinical Trials: Janet T. Holbrook, PhD, MPH, Director; Curtis L. Meinert, PhD, Associate Director; John Dodge, Systems Analyst; Jessica Donithan, Research Coordinator; Nancy Min, PhD, Biostatistician; Laurel Murrow, MSc, Trial Coordinator (former); Jacki Smith, Research Data Assistant; Andrea K. Tibbs, BS, Trial Coordinator; Mark Van Natta, MHS, Biostatistician.

Clinical Centers: The Beth Israel Medical Center, New York: Robert Spiera, MD; Rosanne Berman, MPH; Sandy Enuha, MPH.

Boston University: Peter A. Merkel, MD, MPH; Rondi Gelbard, BS; Melynn Nuite, RN; Aileen Schiller, MS.

The Cleveland Clinic Foundation: Gary S. Hoffman, MD, MS; David Blumenthal, MD; Debora Bork, MFA; Tiffany Clark, CNP; Sonya L. Crook, RN; Leonard H. Calabrese, DO; Sharon Farkas; Sudhakar Sridharan, MD; Kimberly Strom, CNP; William Wilke, MD.

Duke University: E. William St. Clair, MD; Nancy B. Allen, MD; Karen Rodin, RN; Edna Scarlett.

Johns Hopkins University: John H. Stone, MD, MPH; David B. Hellmann, MD; Amanda M. Moore, BS; Lourdes Pinachos, RN, BSN; Michael J. Regan, MD, MRCP; Misty L. Uhlfelder, MPH.

The Mayo Clinic: Ulrich Specks, MD; Kristin Bradt; Kimberly Carlson; Susan Fisher, RN; Boleyn Hammel; Kathy Mieras; Steven Ytterberg, MD. University of California, San Francisco: John C. Davis, MD, MPH; Maureen Fitzpatrick, MPH; Ken Fye, MD; Steve Lund, MSN, NP.

University of Michigan: Joseph McCune, MD; Billie Jo Coomer, BS; Barbara Gilson, RN; Hilary Hafel, MD; Ana Morrel-Samuels, BA; Sandra Neckel, RN.

Resource Centers: The Johns Hopkins University Immune Diseases Laboratory: Noel R. Rose, MD, PhD; C. Lynne Burek, PhD; Jobert Barin, BS; Monica Talor, MS.

Data and Safety Monitoring Board: Paul L. Canner, PhD, Maryland

REFERENCES

1. Merkel PA, Lo GH, Holbrook JT, et al. High incidence of venous thrombotic events among patients with Wegener's granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) study. *Ann Intern Med* 2005;142:620-6.
2. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2006;55:146-9.
3. Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med* 2005;352:351-61.
4. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *N Engl J Med* 2001;344:1222-31.
5. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. *Arterioscler Thromb Vasc Biol* 1999;19:511-8.
6. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism – results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). *Thromb Haemost* 1997;77:444-51.
7. The WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). *Control Clin Trials* 2002;23:450-68.
8. Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's Granulomatosis Etanercept Trial. *Arthritis Rheum* 2003;48:2299-309.
9. Harris EN, Gharavi AE, Patel S, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held April 4 1986. *Clin Exp Immunol* 1987;68:215-22.
10. Harris EN. The Second International Anticardiolipin Standardization Workshop/the Kingston Antiphospholipid Antibody study (KAPS) group. *Am J Clin Pathol* 1990;94:476-84.
11. Harris EN, Pierangeli SS, Birch D. Anticardiolipin wet workshop report: The International Symposium on Antiphospholipid Antibodies. *Am J Clin Pathol* 1994;101:616-24.
12. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. *Lupus* 2002;11:269-75.
13. Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. *Clin Obstet Gynecol* 2001;44:48-57.
14. Cashburn-Budd R, Henderson V, Harley E, Bradwell A, Harris EN, Pierangeli SS. A re-appraisal of the normal cut-off assignment and low positive values for anticardiolipin IgM tests [abstract]. *Arthritis Rheum* 2004;50 Suppl:S69.
15. Pierangeli SS, Stewart M, Silva LK, Harris EN. Report of an anticardiolipin wet workshop during the VIIth International Symposium on Antiphospholipid Antibodies. *J Rheumatol* 1998;25:156-62.
16. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 1994;369:64-7.
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 1996;88:3698-703.
18. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 1995;10:111-3.
19. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G20210A gene variant. *Ann Intern Med* 1998;129:89-92.
20. Petri M. Epidemiology of the antiphospholipid antibody syndrome. *J Autoimmun* 2000;15:145-51.
21. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. *N Engl J Med* 2002;10:752-63.
22. Zanon E, Prandoni P, Vianello F, et al. Anti- β -glycoprotein I antibodies in patients with acute venous thromboembolism: Prevalence and association with recurrent thromboembolism. *Thromb Res* 1999;96:269-74.
23. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *N Engl J Med* 2001;344:1222-31.
24. Heijer DM, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta analysis for published epidemiological studies. *J Thromb Haemost* 2004;3:292-9.
25. Hergesell O, Egbring R, Andrassy K. Presence of anticardiolipin antibodies discriminates between Wegener's granulomatosis and microscopic polyarteritis. *ANCA-Associated Vasculitides: Immunological and Clinical Aspects. Adv Exp Med Bio* 1993;336:393-6.
26. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical association of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. *Am J Med* 1996;101:576-83.
27. Hansen KE, Moore KD, Ortel TL, Allen NB. Antiphospholipid antibodies in patients with Wegener's granulomatosis and polyarteritis nodosa. *Arthritis Rheum* 1999;42:2250-52.
28. Lamprecht P, deGroot K, Csernok E, Liedvogel B, Gross WL. Anticardiolipin antibodies and antibodies to B2-glycoprotein 1 in patients with Wegener's granulomatosis. *Rheumatology Oxford* 2000;39:568-70.
29. Meyer MF, Schenabel A, Schatz H, Gross WL. Lack of association between antiphospholipid antibodies and thrombocytopenia in patients with Wegener's granulomatosis. *Semin Arthritis Rheum* 2001;31:4-11.
30. Von Scheven E, Lu TT, Emery HM, Elder ME, Wara DW. Thrombosis and pediatric Wegener's granulomatosis: Acquired and genetic risk factors for hypercoagulability. *Arthritis Rheum* 2003;49:862-5.